BACKGROUND: Stem cell therapy has been proven to rescue intestinal injury and stimulate intestinal regeneration in necrotizing enterocolitis (NEC). Specifically, stem cells derived from amniotic fluid (AFSCs) and mesenchymal stem cells (MSCs) derived from bone marrow have shown promising results in the treatment of experimental NEC. This study aims to examine the effects of AFSCs and MSCs on the prevention of intestinal injury during experimental NEC. METHODS: Supernatants from AFSC and MSC cultures were collected to perform proteomic analysis. Prior to NEC induction, mice received intraperitoneal injections of phosphate-buffered saline (PBS), 2 × 106 AFSCs, or 2 × 106 MSCs. RESULTS: We found that AFSCs grew faster than MSCs. Proteomic analysis indicated that AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. Administering AFSCs before NEC induction decreased NEC severity and mucosal inflammation. Intestinal proliferation and endogenous stem cell activation were increased after AFSC administration. However, administering MSCs before NEC induction had no beneficial effects. CONCLUSIONS: This study demonstrated that AFSCs and MSCs have different protein release profiles. AFSCs can potentially be used as a preventative strategy for neonates at risk of NEC, while MSCs cannot be used. IMPACT: AFSCs and MSCs have distinct protein secretory profiles, and AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. AFSCs are unique in transiently enhancing healthy intestinal epithelial cell growth, which offers protection against the development of experimental NEC. The prevention of NEC via the administration of AFSCs should be evaluated in infants at great risk of developing NEC or in infants with early signs of NEC.
BACKGROUND: Stem cell therapy has been proven to rescue intestinal injury and stimulate intestinal regeneration in necrotizing enterocolitis (NEC). Specifically, stem cells derived from amniotic fluid (AFSCs) and mesenchymal stem cells (MSCs) derived from bone marrow have shown promising results in the treatment of experimental NEC. This study aims to examine the effects of AFSCs and MSCs on the prevention of intestinal injury during experimental NEC. METHODS: Supernatants from AFSC and MSC cultures were collected to perform proteomic analysis. Prior to NEC induction, mice received intraperitoneal injections of phosphate-buffered saline (PBS), 2 × 106 AFSCs, or 2 × 106 MSCs. RESULTS: We found that AFSCs grew faster than MSCs. Proteomic analysis indicated that AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. Administering AFSCs before NEC induction decreased NEC severity and mucosal inflammation. Intestinal proliferation and endogenous stem cell activation were increased after AFSC administration. However, administering MSCs before NEC induction had no beneficial effects. CONCLUSIONS: This study demonstrated that AFSCs and MSCs have different protein release profiles. AFSCs can potentially be used as a preventative strategy for neonates at risk of NEC, while MSCs cannot be used. IMPACT: AFSCs and MSCs have distinct protein secretory profiles, and AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. AFSCs are unique in transiently enhancing healthy intestinal epithelial cell growth, which offers protection against the development of experimental NEC. The prevention of NEC via the administration of AFSCs should be evaluated in infants at great risk of developing NEC or in infants with early signs of NEC.
Authors: Paolo De Coppi; Georg Bartsch; M Minhaj Siddiqui; Tao Xu; Cesar C Santos; Laura Perin; Gustavo Mostoslavsky; Angéline C Serre; Evan Y Snyder; James J Yoo; Mark E Furth; Shay Soker; Anthony Atala Journal: Nat Biotechnol Date: 2007-01-07 Impact factor: 54.908
Authors: M Thyoka; P de Coppi; S Eaton; K Khoo; N J Hall; J Curry; E Kiely; D Drake; K Cross; A Pierro Journal: Eur J Pediatr Surg Date: 2012-03-20 Impact factor: 2.191
Authors: Augusto Zani; Mara Cananzi; Giuseppe Lauriti; Francesco Fascetti-Leon; Jack Wells; Bernard Siow; Mark F Lythgoe; Agostino Pierro; Simon Eaton; Paolo De Coppi Journal: Eur J Pediatr Surg Date: 2013-07-12 Impact factor: 2.191
Authors: Cüneyt Tayman; Duygu Uckan; Emine Kilic; Ahmet Tulga Ulus; Alparslan Tonbul; Ibrahim Murat Hirfanoglu; Fatma Helvacioglu; Hacer Haltas; Burhan Koseoglu; M Mansur Tatli Journal: Pediatr Res Date: 2011-11 Impact factor: 3.756
Authors: Augusto Zani; Mara Cananzi; Francesco Fascetti-Leon; Giuseppe Lauriti; Virpi V Smith; Sveva Bollini; Marco Ghionzoli; Antonello D'Arrigo; Michela Pozzobon; Martina Piccoli; Amy Hicks; Jack Wells; Bernard Siow; Neil J Sebire; Colin Bishop; Alberta Leon; Anthony Atala; Mark F Lythgoe; Agostino Pierro; Simon Eaton; Paolo De Coppi Journal: Gut Date: 2013-03-24 Impact factor: 23.059
Authors: Chhinder P Sodhi; Raheel Ahmad; Hongpeng Jia; William B Fulton; Carla Lopez; Andres J Gonzalez Salazar; Asuka Ishiyama; Maame Sampah; Steve Steinway; Sanxia Wang; Thomas Prindle; Menghan Wang; David L Steed; Howard Wessel; Ziv Kirshner; Larry R Brown; Peng Lu; David J Hackam Journal: Am J Physiol Gastrointest Liver Physiol Date: 2022-07-12 Impact factor: 4.871
Authors: Rimke Romee de Kroon; Tessa de Baat; Stefania Senger; Mirjam Maria van Weissenbruch Journal: Front Pediatr Date: 2022-03-14 Impact factor: 3.418